More news, no ads
LEARN MOREAn exclusive in-depth interview with the winner of our inaugural Lifetime Achievement Award.
It will fund the clinical development of its brain-penetrating small molecule inhibitors.
He is honoured in the Queen’s Jubilee Birthday Honours 2022.
Sir Greg Winter among speakers as Portway Building premises team looks to accelerate development of synthesised medicines
King Carl XVI Gustaf and Queen Silvia were given an insight into the company’s cutting-edge R&D technology.
The company has brought its R&D teams together in London.
Meanwhile, it expects sales of its Covid-19 vaccine to decline in 2022.
There are an estimated 390 million infections each year.
Growth Works and Eastern AHSN helped the company as it scales.
The Cambridge Science Park company is also working with Roche Diagnostics on a liver cancer pilot study.
It has developed and characterised Affimer proteins against the first target for AffyXell.
An interview with Prof Steve Jackson and CEO Robert Johnson
It extends the total raised to £7m.
The Cambridge biotech wants to ‘drive a revolution in biology’.